Amarin (AMRN) CLO receives 8,013 RSUs and 36,060 ADS stock options

Rhea-AI Filing Summary

Amarin Corporation’s EVP and Chief Legal Officer, Jonathan Provoost, reported new equity awards dated February 1, 2026. He received 8,013 Restricted Stock Units (RSUs) and a stock option for 36,060 American Depositary Shares (ADSs) under the 2020 Stock Incentive Plan.

The 8,013 RSUs vest in three equal installments on January 31, 2027, January 31, 2028 and January 31, 2029. The 36,060 ADS option vests over three years, with 33% vesting on the first anniversary of the grant date and the remainder vesting quarterly over the following eight calendar quarters. The filing notes that, effective April 11, 2025, one ADS represents twenty ordinary shares and that the reported award amounts already reflect this ratio change.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Provoost Jonathan

(Last) (First) (Middle)

C/O AMARIN PHARMA, INC.

440 US HIGHWAY 22

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMARIN CORP PLC\UK [ AMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit(1)	$0	02/01/2026		A		8,013(1)		(2)	(3)	American Depositary Shares(1)	8,013(1)	$0.00	8,013(1)	D
Stock Option (right to buy)	$14.99	02/01/2026		A		36,060(1)		(4)	02/01/2036	American Depositary Shares(1)	36,060(1)	$0.00	36,060(1)	D

Explanation of Responses:

1. Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change.

2. On February 1, 2026, the Reporting Person was granted 8,013 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2027, January 31, 2028 and January 31, 2029.

3. Not applicable.

4. On February 1, 2026, the Reporting Person was granted an option to purchase 36,060 ADSs under the Plan. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 8 calendar quarters on the first day of each May, August, November and February.

	/s/ Jonathan Provoost, by power of attorney	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Amarin (AMRN) report for Jonathan Provoost?

Amarin reported that EVP and Chief Legal Officer Jonathan Provoost received equity awards on February 1, 2026. He was granted 8,013 Restricted Stock Units and a stock option covering 36,060 American Depositary Shares under the company’s 2020 Stock Incentive Plan, both reported at a price of $0.00.

How do the 8,013 RSUs granted to Amarin’s EVP vest over time?

The 8,013 Restricted Stock Units granted to Amarin’s EVP vest in three equal installments. Vesting occurs on January 31, 2027, January 31, 2028 and January 31, 2029, aligning with a multi-year retention structure under the Amarin Corporation plc 2020 Stock Incentive Plan as disclosed.

What are the terms of Jonathan Provoost’s 36,060 ADS stock option at Amarin (AMRN)?

Jonathan Provoost received an option to purchase 36,060 American Depositary Shares with an exercise price of $14.99. The option vests over three years: 33% on the first anniversary of the February 1, 2026 grant, and the remaining balance vests quarterly over eight subsequent calendar quarters.

How did Amarin’s ADS ratio change affect the reported equity awards?

Effective April 11, 2025, one Amarin American Depositary Share represents twenty ordinary shares. The company made proportionate adjustments to outstanding equity awards, and the share amounts reported for the February 1, 2026 RSU and option grants already reflect this ADS ratio change according to the disclosure.

What role does Jonathan Provoost hold at Amarin (AMRN) in this insider filing?

In this insider transaction report, Jonathan Provoost is identified as an officer of Amarin, serving as Executive Vice President and Chief Legal Officer. The Form 4 indicates the equity awards reported are held directly, with no indirect ownership or special beneficial ownership footnote disclosures.

Are Jonathan Provoost’s reported Amarin equity awards direct or indirect holdings?

The filing classifies both the 8,013 Restricted Stock Units and the 36,060 ADS stock option as held under direct ownership. There is no nature-of-ownership qualifier or footnote shifting voting or investment authority to another entity, indicating the awards are directly attributed to the reporting officer.